Atria Investments Inc lessened its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 1.0% in the third quarter, ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...

Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting ...

In a report released on October 31, Yaron Werber from TD Cowen maintained a Buy rating on Argenx Se (ARGX – Research Report), with a ...

argenx SE (NASDAQ:ARGX – Free Report) – Investment analysts at Wedbush increased their Q1 2025 earnings per share (EPS) ...

On Tuesday, Wolfe Research upgraded argenx SE (NASDAQ: ARGX) stock from Peerperform to Outperform with a price target of $697.00. The firm anticipates a positive trajectory for the company through ...

A live webcast of the Guggenheim fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be ...

Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for the supplemental biologics license application (sBLA) for VYVGART ...

Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting catalysts in favor of Argenx – aside from myositis and ...